Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016

  • ID: 3743734
  • Drug Pipelines
  • 60 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • D-Pharm Ltd.
  • Jazz Pharmaceuticals Plc
  • MORE
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016

Summary

‘Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016’, provides in depth analysis on Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted pipeline therapeutics.

The report provides comprehensive information on the Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1)
- The report reviews Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • D-Pharm Ltd.
  • Jazz Pharmaceuticals Plc
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) Overview

Therapeutics Development

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Products under Development by Stage of Development

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Products under Development by Therapy Area

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Products under Development by Indication

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Products under Development by Companies

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Products under Development by Universities/Institutes

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Companies Involved in Therapeutics Development

D-Pharm Ltd.

Jazz Pharmaceuticals Plc

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Drug Profiles

CT-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

defibrotide sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rPAI-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-216 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5275 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5509 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Dormant Projects

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Discontinued Products

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Featured News & Press Releases

Mar 30, 2016: FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow

Mar 30, 2016: Jazz Pharmaceuticals Announces Webcast for Defitelio (defibrotide sodium) Investor Update

Feb 18, 2016: Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting

Feb 01, 2016: Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD

Sep 30, 2015: Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease

May 14, 2015: D-Pharm receives final report for its Phase 2 clinical study of THR-18 in acute stroke patients treated with tPA

Feb 12, 2015: Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease at BMT Tandem Meetings

Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA

Dec 11, 2014: Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease

Dec 02, 2014: Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by D-Pharm Ltd., H1 2016

Pipeline by Jazz Pharmaceuticals Plc, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • D-Pharm Ltd.
  • Jazz Pharmaceuticals Plc
  • MORE
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) pipeline Target constitutes close to 11 molecules. Out of which approximately 4 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 6 molecules, respectively.

Our latest report Plasminogen Activator Inhibitor-1 – Pipeline Review, H1 2016, outlays comprehensive information on the Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
D-Pharm Ltd.
Jazz Pharmaceuticals Plc
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll